Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,024,626
  • Shares Outstanding, K 218,699
  • Annual Sales, $ 2,159 M
  • Annual Income, $ 446,910 K
  • 60-Month Beta 1.08
  • Price/Sales 8.95
  • Price/Cash Flow 35.31
  • Price/Book 8.24
Trade INCY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.46
  • Number of Estimates 2
  • High Estimate 0.51
  • Low Estimate 0.41
  • Prior Year 0.62
  • Growth Rate Est. (year over year) -25.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.31 +1.03%
on 10/28/20
98.47 -12.47%
on 10/12/20
-1.24 (-1.42%)
since 09/29/20
3-Month
82.98 +3.87%
on 09/24/20
102.61 -16.00%
on 08/03/20
-11.85 (-12.09%)
since 07/29/20
52-Week
62.48 +37.95%
on 03/23/20
110.36 -21.90%
on 07/07/20
+2.84 (+3.41%)
since 10/29/19

Most Recent Stories

More News
Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

INCY : 86.98 (-0.01%)
NVS : 78.02 (-0.43%)
GERN : 1.7800 (-0.56%)
RGNX : 28.91 (+1.58%)
Pooled Results from Incyte's TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments

Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies - TRuE-AD1 and TRuE-AD2 - evaluating ruxolitinib...

INCY : 86.98 (-0.01%)
What's in Store for Ligand (LGND) This Earnings Season?

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

GILD : 57.76 (-1.63%)
INCY : 86.98 (-0.01%)
AMGN : 217.88 (+0.69%)
LGND : 81.24 (-3.77%)
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

AZN : 51.10 (+0.24%)
INCY : 86.98 (-0.01%)
MRNA : 72.73 (+10.63%)
VRTX : 206.84 (-0.72%)
Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma

Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma

INCY : 86.98 (-0.01%)
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.

RHHBY : 40.1200 (+0.07%)
INCY : 86.98 (-0.01%)
BMY : 57.67 (-0.16%)
AMGN : 217.88 (+0.69%)
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer

It’s been a year and a half since the US Food and Drug Administration approved the first targeted ...

ONCY : 2.06 (-1.90%)
INCY : 86.98 (-0.01%)
AZN : 51.10 (+0.24%)
OCX : 1.5299 (-2.55%)
ERYP : 5.24 (+1.95%)
ONC.TO : 2.74 (-2.14%)
Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer

, /PRNewswire/ --   – It's been a year and a half since the US Food and Drug Administration approved the  in the treatment of triple-negative breast cancer (TNBC) leading the way to what's been hailed...

ONCY : 2.06 (-1.90%)
ONC.TO : 2.74 (-2.14%)
AZN : 51.10 (+0.24%)
OCX : 1.5299 (-2.55%)
INCY : 86.98 (-0.01%)
ERYP : 5.24 (+1.95%)
Incyte to Report Third Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, November 5, 2020.

INCY : 86.98 (-0.01%)
After Yesterday's Decline of 1.58%, Incyte Corp Offers Investors Better Value

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $89.15 to a high of $90.74. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $90.22...

INCY : 86.98 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 89.32
1st Resistance Point 88.16
Last Price 86.98
1st Support Level 85.57
2nd Support Level 84.14

See More

52-Week High 110.36
Fibonacci 61.8% 92.07
Last Price 86.98
Fibonacci 50% 86.42
Fibonacci 38.2% 80.77
52-Week Low 62.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar